ArticlePloS one2022

Mesenchymal stromal cell therapy compared to SGLT2-inhibitors and usual care in treating diabetic kidney disease: A cost-effectiveness analysis.

Luke E Barry et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.